Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

The groundbreaking injectable drug offers significant weight-loss and glycemic control at a fraction of U.S. prices, entering a market with over 200 million affected individuals.

Mounjaro, a once-weekly injectable drug, is now available in India following approval from the Central Drugs Standard Control Organisation (CDSCO).
The drug targets obesity and type 2 diabetes by activating GIP and GLP-1 hormone receptors, helping regulate appetite and reduce weight.
Clinical trials showed participants lost an average of 21.8 kg at the highest dose over 72 weeks, alongside substantial improvements in blood sugar levels.
Priced at ₹3,500 for a 2.5 mg dose and ₹4,375 for a 5 mg dose, Mounjaro is significantly cheaper in India compared to Western markets.
Experts emphasize the need for medical supervision in its use, particularly given the complexities of obesity and diabetes treatment.